PepGen (PEPG)
(Delayed Data from NSDQ)
$9.27 USD
-0.54 (-5.50%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $9.33 +0.06 (0.65%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
PepGen, Inc. [PEPG]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
How Does DMD Drug Development Change Post-Elevidys?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECTing With Management - Thoughts on Upcoming PGN-EDO51 Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead To Near-Term Data Readout With CONNECT-1
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECT Can Achieve Clinically Meaningful Dystrophin Expression - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
PGN-EDODM1 has the Potential to Achieve > 30% Splicing Correction?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Making CONNECTions With PGN-EDO51 Data Tracking to Mid-2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
MOMENTUM Read Through: Thoughts on PEPG''s PGN-EDO51
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Bullish Ahead of CONNECT1-EDO51 in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
FDA?s Lifting of Full Clinical Hold Validates Safety of Cell Penetrating Peptide Platform?Implications for PGN-EDODM1
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CTA Clearance Might Help Accelerate PGN-EDODM1 Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
HV Repeat Dosing Data Builds the Foundation for CONNECT1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Making CONNECTions Happen; Phase 2 PGN-EDO51 Efforts On Track [2Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L